Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Open accessAbstract
Key Points: CDK6 is a critical effector of MLL fusions in myeloid leukemogenesis. Genetic and pharmacologic inhibition of CDK6 overcome the differentiation block associated with MLL-rearranged AML.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Multiple types of leukemia cells are dependent on CDK6 for survival, including MLL and Ph+ ALL.
“Multiple types of leukemia cells are dependent on CDK6 for survival, including mixed-lineage leukemia (MLL) [123] and Philadelphia chromosome-positive ALL (Ph+ ALL) [9].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,869 · see citing works
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,348 · see citing works
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747 · see citing works
Grimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936 · see citing works
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · see citing works
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1× · see citing works
“A key functional feature of mixed-lineage leukemia (MLL) rearrangements is their ability to confer leukemia-initiating activity to hematopoietic stem and progenitor cells (HSPC).(5,6) MLL fusions are characterized by loss of the C-terminal H3K4 methyltransferase domain, and their leukemogenic activity is dependent on…”
Self-citationInhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,512 · see citing works
Self-citationA p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann, E., Plaen, E. D., Hankeln, T., Büschenfelde, K. M. Z., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,153 · see citing works
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J. J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 926 · see citing works
Self-citationMLL-rearranged Leukemia is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K., Zhu, N., Sinha, A., Vempati, S., Faber, J., Krivtsov, A., Feng, Z.-H., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 896 · see citing works
Self-citationThe Wnt/β-catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML
Wang, Y., Krivtsov, A., Sinha, A., North, T., Goessling, W., Feng, Z.-H., Zon, L., & Armstrong, S. (2010) · Science · doi:10.1126/science.1186624 · Cited by 812 · see citing works
Self-citationMammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793 · see citing works
Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors
Kutner, R. H., Zhang, X., & Reiser, J. (2009) · Nature Protocols · doi:10.1038/nprot.2009.22 · Cited by 670 · see citing works
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A. M., & Sauvageau, G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3714 · Cited by 640 · see citing works
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia
Somervaille, T. C. P., & Cleary, M. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.020 · Cited by 582 · see citing works
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., Ciceri, F., Blaser, J. G., Greystoke, B. F., Jordan, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.014 · Cited by 566 · see citing works
Scholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 539 · see citing works
Self-citationHox genes in hematopoiesis and leukemogenesis
Argiropoulos, B., & Humphries, R. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210760 · Cited by 492 · see citing works
The MLL recombinome of acute leukemias in 2013
Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T. S., Emerenciano, M., Pombo‐de‐Oliveira, M. S., Renneville, A., Villarèse, P., Macintyre, E. A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.135 · Cited by 491 · see citing works
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
Grembecka, J. E., He, S., Shi, A., Purohit, T., Muntean, A. G., Sorenson, R. J., Showalter, H. D., Murai, M. J., Belcher, A. M., Hartley, T., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.773 · Cited by 468 · see citing works
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · see citing works
Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5476 · Cited by 399 · see citing works
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification
Mueller, D., Bach, C., Zeisig, D. T., García-Cuéllar, M.-P., Monroe, S., Sreekumar, A., Zhou, R., Nesvizhskii, A. I., Chinnaiyan, A. M., Hess, J. L., et al. (2007) · Blood · doi:10.1182/blood-2007-05-090514 · Cited by 396 · see citing works
Molecular pathogenesis of mantle cell lymphoma
Jares, P., Colomer, D., & Campo, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61272 · Cited by 384 · see citing works
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366 · see citing works
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358 · see citing works
HOXA9 is required for survival in human MLL-rearranged acute leukemias.
Faber, J., Krivtsov, A., Stubbs, M. C., Wright, R. D., Davis, T. N., van den Heuvel-Eibrink, M. M., Zwaan, C., Kung, A., & Armstrong, S. (2009) · Blood · doi:10.1182/blood-2007-09-113597 · Cited by 345 · see citing works
Self-citationThe molecular biology of mixed lineage leukemia
Slany, R. K. (2009) · Haematologica · doi:10.3324/haematol.2008.002436 · Cited by 321 · see citing works
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313 · see citing works
Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom)Preprint
Mohan, M., Herz, H., Takahashi, Y.-H., Lin, C., Lai, K. C., Zhang, Y., Washburn, M. P., Florens, L. A., & Shilatifard, A. (2010) · Genes & Development · doi:10.1101/gad.1898410 · Cited by 312 · see citing works
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299 · see citing works
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.Preprint
Guenther, M., Lawton, L. N., Rozovskaia, T., Frampton, G., Levine, S., Volkert, T. L., Croce, C., Nakamura, T., Canaani, E., & Young, R. (2008) · Genes & Development · doi:10.1101/gad.1741408 · Cited by 288 · see citing works
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
Wang, Z., Smith, K. S., Murphy, M., Piloto, O., Somervaille, T. C. P., & Cleary, M. L. (2008) · Nature · doi:10.1038/nature07284 · Cited by 265 · see citing works
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
Yeung, J., Esposito, M., Gandillet, A., Zeisig, B., Griessinger, E., Bonnet, D., & So, C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.032 · Cited by 264 · see citing works
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223 · see citing works
Self-citationRequirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation
Jo, S. Y., Granowicz, E. M., Maillard, I. P., Thomas, D. G., & Hess, J. L. (2011) · Blood · doi:10.1182/blood-2010-12-327668 · Cited by 198 · see citing works
RGB marking facilitates multicolor clonal cell tracking
Riecken, K., Thomaschewski, M., Warlich, M., Volz, T., Cornils, K., Niebuhr, B., Täger, M., Lütgehetmann, M., Pollok, J., Stocking, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2338 · Cited by 174 · see citing works
CBX8, a Polycomb Group Protein, Is Essential for MLL-AF9-Induced Leukemogenesis
Tan, J., Jones, M., Koseki, H., Nakayama, M., Muntean, A. G., Maillard, I. P., & Hess, J. L. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.008 · Cited by 172 · see citing works
Biswas, D., Milne, T. A., Basrur, V., Kim, J., Elenitoba‐Johnson, K. S. J., Allis, C. D., & Roeder, R. G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111498108 · Cited by 168 · see citing works
Cyclin dependent kinases in cancer
Canavese, M., Santo, L., & Raje, N. S. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19589 · Cited by 162 · see citing works
Corcoran, M., Mould, S., Orchard, J., Ibbotson, R., Chapman, R., Boright, A. P., Platt, C., Tsui, L.-C., Scherer, S. W., & Oscier, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203033 · Cited by 153 · see citing works
Cyclin-Dependent Kinase 6 Is a Chromatin-Bound Cofactor for NF-κB-Dependent Gene Expression
Handschick, K., Beuerlein, K., Jurida, L., Bartkuhn, M., Müller, H., Soelch, J., Weber, A., Dittrich-Breiholz, O., Schneider, H., Scharfe, M., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.002 · Cited by 141 · see citing works
Wang, Q.-F., Wu, G., Mi, S.-L., He, F., Wu, J., Dong, J.-F., Luo, R., Mattison, R., Kaberlein, J. J., Prabhakar, S., et al. (2011) · Blood · doi:10.1182/blood-2010-12-324699 · Cited by 134 · see citing works
A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis
Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G., Chang, R., Guo, Z., Dose, M., Mao, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2473 · Cited by 116 · see citing works
Fujimoto, T., Anderson, K., Jacobsen, S. E. W., Nishikawa, S.-I., & Nerlov, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601675 · Cited by 110 · see citing works
How to manage acute promyelocytic leukemia
Mi, J.-Q., Li, J., Shen, Z.-X., Chen, S.-J., & Chen, Z. (2012) · Leukemia · doi:10.1038/leu.2012.57 · Cited by 97 · see citing works
Gröschel, S., Schlenk, R., Engelmann, J., Ročková, V., Teleanu, V., Kühn, M. W. M., Eiwen, K., Erpelinck, C. A. J., Havermans, M., Lübbert, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5505 · Cited by 97 · see citing works
Chilosi, M., Doglioni, C., Yan, Z., Lestani, M., Menestrina, F., Sorio, C., Benedetti, A., Vinante, F., Pizzolo, G., & Inghirami, G. (1998) · Europe PMC (PubMed Central) · Cited by 96 · see citing works
A role for MEIS1 in MLL-fusion gene leukemia
Kumar, A. R., Li, Q., Hudson, W. A., Chen, W., Sam, T. N., Yao, Q., Lund, E. A., Wu, B., Kowal, B. J., & Kersey, J. H. (2008) · Blood · doi:10.1182/blood-2008-06-163287 · Cited by 96 · see citing works
Krauter, J., Wagner, K., Schäfer, I., Marschalek, R., Meyer, C., Heil, G., Schaich, M., Ehninger, G., Niederwieser, D., Krahl, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7981 · Cited by 91 · see citing works
Towards systematic functional characterization of cancer genomes
Boehm, J. S., & Hahn, W. C. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3013 · Cited by 84 · see citing works
Self-citationCDK6 kinase activity is required for thymocyte development
Hu, M. G., Deshpande, A., Schlichting, N., Hinds, E. A., Mao, C., Dose, M., Hu, G., Etten, R. A. V., Gounari, F., & Hinds, P. W. (2011) · Blood · doi:10.1182/blood-2010-08-300517 · Cited by 84 · see citing works
A Missing Link in Genotype-Directed Cancer Therapy
Bernards, R. (2012) · Cell · doi:10.1016/j.cell.2012.10.014 · Cited by 82 · see citing works
MLL-rearranged leukemias: insights from gene expression profiling
Armstrong, S. A., Golub, T. R., & Korsmeyer, S. J. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)00196-3 · Cited by 80 · see citing works
Self-citationEpigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB
Kuo, H.-P., Wang, Z., Lee, D., 岩崎, 正., Duque‐Afonso, J., Wong, S. H. K., Lin, C.-H., Figueroa, M. E., Su, J., Lemischka, I. R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.019 · Cited by 80 · see citing works
Essential role of DOT1L in maintaining normal adult hematopoiesis
Nguyen, A. T., He, J., Taranova, O., & Zhang, Y. (2011) · Cell Research · doi:10.1038/cr.2011.115 · Cited by 71 · see citing works
Whiteway, S. L., Harris, P. S., Venkataraman, S., Alimova, I. N., Birks, D. K., Donson, A. M., Foreman, N. K., & Vibhakar, R. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1000-7 · Cited by 67 · see citing works
CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling
Faber, K., Bullinger, L., Ragu, C., Garding, A., Mertens, D., Miller, C. V., Martin, D., Walcher, D., Döhner, K., Döhner, H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64745 · Cited by 55 · see citing works
Self-citationDolgin, E. (2013) · Nature Medicine · doi:10.1038/nm.3245 · Cited by 11 · see citing works
Flagged first, then by citations
1 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,780 · see citing works
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 544 · see citing works
Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR
Li, W., Köster, J., Xu, H., Chen, C.-H., Xiao, T., Liu, J. S., Brown, M. A., & Liu, X. S. (2015) · Genome biology · doi:10.1186/s13059-015-0843-6 · Cited by 492 · see citing works
Krivtsov, A., Evans, K., Gadrey, J. Y., Eschle, B. K., Hatton, C., Uckelmann, H., Ross, K., Perner, F., Olsen, S., Pritchard, T., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.001 · Cited by 369 · see citing works
Self-citationMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
Grimwade, D. J., Ivey, A., & Huntly, B. J. P. (2015) · Blood · doi:10.1182/blood-2015-07-604496 · Cited by 451 · see citing works
Self-citationMLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Winters, A. C., & Bernt, K. M. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00004 · Cited by 402 · see citing works
CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells
Laurenti, E., Frelin, C., Xie, S. Z.-J., Ferrari, R., Dunant, C. F., Zandi, S., Neumann, A. L., Plumb, I., Doulatov, S. R., Chen, J., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.01.017 · Cited by 340 · see citing works
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 339 · see citing works
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F. R., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 301 · see citing works
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
Scheicher, R., Hoelbl‐Kovacic, A., Bellutti, F., Tigan, A.-S., Prchal‐Murphy, M., Heller, G., Schneckenleithner, C., Salazar‐Roa, M., Zöchbauer‐Müller, S., Zuber, J. A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-584417 · Cited by 263 · see citing works
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204 · see citing works
Nebenfuehr, S., Kollmann, K., & Sexl, V. (2020) · International Journal of Cancer · doi:10.1002/ijc.33054 · Cited by 185 · see citing works
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
Yamashita, M., Dellorusso, P. V., Olson, O. C., & Passegue, E. A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0260-3 · Cited by 182 · see citing works
Palanichamy, J. K., Tran, T. M., Howard, J. M., Contreras, J. R., Fernando, T. R., Sterne-Weiler, T., Katzman, S. J., Toloue, M., Yan, W., Basso, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80046 · Cited by 169 · see citing works
Targeting CDK6 in cancer: State of the art and new insights
Tadesse, S., Yu, M., Kumarasiri, M., Le, B. T., & Wang, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1084445 · Cited by 166 · see citing works
LKB1, Salt-Inducible Kinases, and MEF2C are linked dependencies in acute myeloid leukemia
Tarumoto, Y., Lu, B., Somerville, T., Huang, Y.-H., Milazzo, J. P., Wu, X.-L. S., Klingbeil, O., Demerdash, O. E., Shi, J.-W., & Vakoc, C. R. (2018) · Molecules and Cells · doi:10.1016/j.molcel.2018.02.011 · Cited by 132 · see citing works
Uras, I. Z., Walter, G. J., Scheicher, R., Bellutti, F., Prchal‐Murphy, M., Tigan, A.-S., Valent, P., Heidel, F. H., Kubicek, S., Scholl, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683581 · Cited by 138 · see citing works
Self-citationmiR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia
Jiang, X., Hu, C., Arnovitz, S., Bugno, J., Yu, M., Zuo, Z., Chen, P., Huang, H., Ulrich, B., Gurbuxani, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11452 · Cited by 158 · see citing works
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition
Dzama, M. M., Steiner, M., Rausch, J., Sasca, D., Schönfeld, J., Kunz, K., Taubert, M. C., McGeehan, G. M., Chen, C.-W. D., Mupo, A., et al. (2020) · Blood · doi:10.1182/blood.2020005037 · Cited by 133 · see citing works
Self-citationProteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126 · see citing works
Kuntimaddi, A., Achille, N. J., Thorpe, J., Lokken, A. A., Singh, R., Hemenway, C. S., Adli, M., Zeleznik‐Le, N. J., & Bushweller, J. H. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.004 · Cited by 120 · see citing works
Targeting cell cycle regulators in hematologic malignancies
Aleem, E. A., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 122 · see citing works
Martinez-Soria, N., McKenzie, L., Draper, J. E., Ptasinska, A., Issa, H., Potluri, S., Blair, H. J., Pickin, A., Isa, A., Chin, P. S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.015 · Cited by 120 · see citing works
岩崎, 正., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.08.008 · Cited by 119 · see citing works
Baker, A., Gregory, G. P., Verbrugge, I., Kats, L. M., Hilton, J. J., Vidacs, E., Lee, E. M., Lock, R. B., Zuber, J. A., Shortt, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1070 · Cited by 117 · see citing works
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
Dafflon, C., Craig, V. J., Méreau, H., Gräsel, J., Engstler, B. S., Hoffman, G., Nigsch, F., Gaulis, S., Barys, L., Ito, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.327 · Cited by 115 · see citing works
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Pikman, Y., Alexe, G., Roti, G., Conway, A. S., Furman, A. A., Lee, E. S., Place, A. E., Kim, S., Saran, C., Modiste, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2869 · Cited by 112 · see citing works
LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia
Fernando, T. R., Rodriguez-Malave, N. I., Waters, E. V., Yan, W., Casero, D., Basso, G., Pigazzi, M., & Rao, D. S. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0006-t · Cited by 104 · see citing works
Ying, M., Shao, X., Jing, H., Liu, Y., Qi, X., Cao, J., Chen, Y., Xiang, S., Song, H., Hu, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813139 · Cited by 104 · see citing works
NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.
Sasca, D., Szybinski, J., Schüler, A., Shah, V., Heidelberger, J. B., Haehnel, P. S., Dolnik, A., Kriege, O., Fehr, E.-M., Gebhardt, W., et al. (2019) · Blood · doi:10.1182/blood-2018-12-889725 · Cited by 93 · see citing works
Self-citationMLL-Rearranged Acute Lymphoblastic Leukemia
Chaer, F. E., Keng, M. K., & Ballen, K. K. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00582-5 · Cited by 92 · see citing works
Brenner, A. K., Reikvam, H., Lavecchia, A., & Bruserud, Ø. (2014) · Molecules · doi:10.3390/molecules191118414 · Cited by 86 · see citing works
A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition
Soto‐Feliciano, Y. M., Rivera, F. J. S., Perner, F., Barrows, D., Kastenhuber, E. R., Ho, Y.-J., Carroll, T., Xiong, Y., Anand, D., Soshnev, A. A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0416 · Cited by 84 · see citing works
Self-citationUpdate on rational targeted therapy in AML
Shafer, D. A., & Grant, S. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.02.001 · Cited by 79 · see citing works
Lee, D. J., & Zeidner, J. F. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1678583 · Cited by 77 · see citing works
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Wu, X., Yang, X., Xiong, Y., Li, R., Ito, T., Ahmed, T. A., Karoulia, Z., Adamopoulos, C., Wang, H., Wang, L., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00174-z · Cited by 74 · see citing works
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
Sandhöfer, N., Metzeler, K. H., Rothenberg, M., Herold, T., Tiedt, S., Groiß, V., Carlet, M., Walter, G., Hinrichsen, T., Wachter, O., et al. (2014) · Leukemia · doi:10.1038/leu.2014.305 · Cited by 75 · see citing works
Self-citationThe molecular mechanics of mixed lineage leukemia
Slany, R. K. (2016) · Oncogene · doi:10.1038/onc.2016.30 · Cited by 72 · see citing works
CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia
Schmoellerl, J., Barbosa, I. A. M., Eder, T., Brandstoetter, T., Schmidt, L., Maurer, B., Troester, S., Pham, H. T. T., Mohanty, S., Ebner, J., et al. (2020) · Blood · doi:10.1182/blood.2019003267 · Cited by 74 · see citing works
ZFP36L1 promotes monocyte/macrophage differentiation by repressing CDK6
Chen, M., Dong, L., Zhang, X., Yin, X.-L., Ning, H., Shen, C., Su, R. J., Li, F., Li, S., Ma, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep16229 · Cited by 70 · see citing works
Differentiation therapy of myeloid leukemia: four decades of development
Madan, V., & Koeffler, H. P. (2020) · Haematologica · doi:10.3324/haematol.2020.262121 · Cited by 70 · see citing works
Ng, Y. L. D., Ramberger, E., Bohl, S., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28515-1 · Cited by 68 · see citing works
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia
Rudat, S., Pfaus, A., Cheng, Y., Holtmann, J., Ellegast, J. M., Bühler, C., Marcantonio, D. D., Martı́nez, E., Göllner, S., Wickenhauser, C., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0102-4 · Cited by 68 · see citing works
Self-citationHandschuh, L. (2019) · Journal of Oncology · doi:10.1155/2019/7239206 · Cited by 65 · see citing works
CDK6 Inhibition: A Novel Approach in AML Management
Uras, I. Z., Sexl, V., & Kollmann, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072528 · Cited by 65 · see citing works
miR-139-5p controls translation in myeloid leukemia through EIF4G2
Emmrich, S., Engeland, F., El-Khatib, M., Henke, K., Obulkasim, A., Schöning, J., Katsman-Kuipers, J. E., Zwaan, C. M., Pich, A., Starý, J., et al. (2015) · Oncogene · doi:10.1038/onc.2015.247 · Cited by 64 · see citing works
Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer
Mills, C. C., Kolb, E. A., & Sampson, V. B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2066 · Cited by 59 · see citing works
MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors
Chen, X., Burkhardt, D. B., Hartman, A. A., Hu, X., Eastman, A. E., Sun, C., Wang, X., Zhong, M., Krishnaswamy, S., & Guo, S. (2019) · Nature Communications · doi:10.1038/s41467-019-13666-5 · Cited by 58 · see citing works
Gao, S.-M., Zhou, B., Li, H.-Y., Huang, X., Wu, Y.-F., Xing, C.-Y., Yu, X.-Z., & Ji, Y.-H. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.08.005 · Cited by 59 · see citing works
Aubrey, B., Cutler, J., Bourgeois, W., Donovan, K., Gu, S., Hatton, C., Perlee, S., Perner, F., Rahnamoun, H., Theall, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00366-1 · Cited by 50 · see citing works
Self-citationRNA-Binding Proteins in Acute Leukemias
Schuschel, K., Helwig, M., Hüttelmaier, S., Heckl, D., Klusmann, J., & Hoell, J. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103409 · Cited by 57 · see citing works
Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines
Zhang, Z., Golomb, L., & Meyerson, M. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2428 · Cited by 56 · see citing works
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53 · see citing works
Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia
Ling, V., Straube, J., Godfrey, W. A., Haldar, R., Janardhanan, Y., Cooper, L. T., Bruedigam, C., Cooper, E., Shirazi, P. T., Jacquelin, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01755-2 · Cited by 49 · see citing works
Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia
James, A. R., Schroeder, M. P., Neumann, M., Bastian, L., Eckert, C., Gökbuget, N., Tanchez, J. O., Schlee, C., Isaakidis, K., Schwartz, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0692-3 · Cited by 50 · see citing works
H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma.
Li, C., Lei, B., Huang, S., Zheng, M., Liu, Z., Li, Z., & Deng, Y. (2015) · Europe PMC (PubMed Central) · Cited by 48 · see citing works
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 47 · see citing works
Maurer, B., Brandstoetter, T., Kollmann, S., Sexl, V., & Prchal‐Murphy, M. (2020) · Haematologica · doi:10.3324/haematol.2020.256313 · Cited by 46 · see citing works
Cell cycle regulation and hematologic malignancies
Dai, Y., Jin, F., Wu, W., & Kumar, S. K. (2019) · Blood Science · doi:10.1097/bs9.0000000000000009 · Cited by 46 · see citing works
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia
Rahaman, M. H., Yu, Y., Zhong, L., Adams, J., Lam, F., Li, P., Noll, B., Milne, R. W., Peng, J., & Wang, S. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0661-2 · Cited by 42 · see citing works
An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
Lopez, S., Voisset, E., Tisserand, J. C., Mosca, C., Prébet, T., Santamarı́a, D., Dubreuil, P. C., & Sepulveda, P. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9965 · Cited by 39 · see citing works
Transcriptional activation by MLL fusion proteins in leukemogenesis.
Yokoyama, A. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2016.10.014 · Cited by 35 · see citing works
Wang, X., Jin, P., Zhang, Y., & Wang, K. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03566-2 · Cited by 33 · see citing works
The IRX1/HOXA connection: insights into a novel t(4;11)- specific cancer mechanism
Kühn, A., Löscher, D., & Marschalek, R. (2016) · Oncotarget · doi:10.18632/oncotarget.9241 · Cited by 33 · see citing works
The RUNX1/RUNX1T1 network: translating insights into therapeutic options
Swart, L. E., & Heidenreich, O. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.005 · Cited by 32 · see citing works
Bortolozzi, R., Mattiuzzo, E., Trentin, L., Accordi, B., Basso, G., & Viola, G. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.050 · Cited by 31 · see citing works
miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential
Meyer, S. E., Muench, D. E., Rogers, A. M., Newkold, T. J., Orr, E., O'Brien, E. J., Perentesis, J. P., Doench, J. G., Lal, A., Morris, P. J., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171312 · Cited by 30 · see citing works
Cdk6 contributes to cytoskeletal stability in erythroid cells
Uras, I. Z., Scheicher, R., Kollmann, K., Glösmann, M., Prchal‐Murphy, M., Tigan, A.-S., Fux, D. A., Altamura, S., Neves, J., Muckenthaler, M. U., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159947 · Cited by 30 · see citing works
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
Bertoli, S., Boutzen, H., David, L., Larrue, C., Vergez, F., Fernandez-Vidal, A., Yuan, L., Tamburini, J., Demur, C., Delabesse, É., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5706 · Cited by 29 · see citing works
p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis
Li, M., Yang, J., Liu, K., Yang, J., Zhan, X., Wang, L., Shen, X., Chen, J., & Mao, Z. (2020) · Journal of Cancer · doi:10.7150/jca.35479 · Cited by 29 · see citing works
Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia
Gurnari, C., Pagliuca, S., & Visconte, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228505 · Cited by 31 · see citing works
Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL
Bardini, M., Trentin, L., Rizzo, F., Vieri, M., Savino, A. M., Castro, P. G., Fazio, G., Roon, E. H. J. V., Kerstjens, M. J., Smithers, N. N., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1123 · Cited by 29 · see citing works
Numata, A., Kwok, H.-S., Kawasaki, A., Li, J., Zhou, Q.-L., Kerry, J., Benoukraf, T., Bararia, D., Li, F., Ballabio, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03854-0 · Cited by 28 · see citing works
Targeting CDK6 and BCL2 Exploits the “MYB Addiction” of Ph+ Acute Lymphoblastic Leukemia
Dominici, M. D., Porazzi, P., Soliera, A. R., Mariani, S. A., Addya, S., Fortina, P. M., Peterson, L. F., Spinelli, O., Rambaldi, A., Martinelli, G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2644 · Cited by 27 · see citing works
TBP loading by AF4 through SL1 is the major rate-limiting step in MLL fusion-dependent transcription
Okuda, H., Takahashi, S., Takaori-Kondo, A., & Yokoyama, A. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1222337 · Cited by 26 · see citing works
High rates of submicroscopic aberrations in karyotypically normal acute lymphoblastic leukemia
Othman, M. A. K., Melo, J. B., Carreira, I. M., Rinčić, M., Glaser, A., Grygalewicz, B., Gruhn, B., Wilhelm, K., Rittscher, K., Meyer, B., et al. (2015) · Molecular Cytogenetics · doi:10.1186/s13039-015-0153-4 · Cited by 26 · see citing works
Hernandez Maganhi, S., Jensen, P., Caracelli, I., Zukerman Schpector, J., Fröhling, S., & Friedman, R. (2017) · Protein Science · doi:10.1002/pro.3135 · Cited by 25 · see citing works
Self-citationGiovanni, C. D., Novellino, E., Chilin, A., Lavecchia, A., & Marzaro, G. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1234603 · Cited by 25 · see citing works
Tomić, B., Smoljo, T., Lalić, H., Dembitz, V., Batinić, J., Batinić, D., Bedalov, A., & Višnjić, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-15520-z · Cited by 25 · see citing works
Richter, A., Schoenwaelder, N., Sender, S., Junghanss, C., & Maletzki, C. (2021) · Cancers · doi:10.3390/cancers13102497 · Cited by 23 · see citing works
Murine Models of Acute Myeloid Leukemia
Kurtz, K. J., Conneely, S. E., O'Keefe, M. B., Wohlan, K., & Rau, R. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.854973 · Cited by 23 · see citing works
ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia
Germanò, G., Morello, G., Aveic, S., Pinazza, M., Minuzzo, S. A., Frasson, C., Persano, L., Bonvini, P., Viola, G., Bresolin, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15387 · Cited by 23 · see citing works
Zhou, B., Jin, X.-H., Jin, W., Huang, X., Wu, Y.-F., Li, H.-Y., Zhu, W., Qin, X., Ye, H.-G., & Gao, S.-M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02384-y · Cited by 27 · see citing works
Rasouli, M., Troester, S., Grebien, F., Goemans, B. F., Zwaan, C. M., & Heidenreich, O. T. (2024) · HemaSphere · doi:10.1002/hem3.70013 · Cited by 22 · see citing works
Adriaanse, F. R. S., Schneider, P., Arentsen-Peters, S. T. C. J. M., da Fonseca, A. M. N., Stutterheim, J., Pieters, R., Zwaan, C. M., & Stam, R. W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116020 · Cited by 22 · see citing works
Emerging cell cycle inhibitors for acute myeloid leukemia
Zahr, A. A., & Borthakur, G. M. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1330885 · Cited by 21 · see citing works
CDK6 Is a Therapeutic Target in Myelofibrosis
Dutta, A., Nath, D., Yang, Y., Le, B. T., & Mohi, G. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0590 · Cited by 21 · see citing works
Kumarasamy, V. M., Gao, Z., Zhao, B., Jiang, B., Rubin, S. M., Burgess, K., Witkiewicz, A. K., & Knudsen, E. S. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02399-4 · Cited by 20 · see citing works
Targeting chromatin modifying complexes in acute myeloid leukemia
Schurer, A., Glushakow-Smith, S. G., & Gritsman, K. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae089 · Cited by 19 · see citing works
Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin.
Man, N., Sun, X.-J., Tan, Y., Garcia-Cao, M., Liu, F., Cheng, G.-Y., Hatlen, M. A., Xu, H.-M., Shah, R., Chastain, N., et al. (2016) · Blood · doi:10.1182/blood-2015-11-677708 · Cited by 22 · see citing works
Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
Uras, I. Z., Maurer, B., Nebenfuehr, S., Zojer, M., Valent, P., & Sexl, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123987 · Cited by 19 · see citing works
CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML
Schmalzbauer, B. S., Thondanpallil, T., Heller, G., Schirripa, A., Sperl, C.-M., Mayer, I. M., Knab, V. M., Nebenfuehr, S., Zojer, M., Müller, A. C., et al. (2022) · Cancers · doi:10.3390/cancers14061554 · Cited by 17 · see citing works
HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML
Li, Z., Wang, F., Tian, X., Long, J., Ling, B., Zhang, W., Xu, J., & Liang, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02007-4 · Cited by 17 · see citing works
Xu, J. J., Chalk, A. M., Nikolić, I., Simpson, K. J., Smeets, M. F. M. A., & Walkley, C. R. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004571 · Cited by 17 · see citing works
NFkB is activated by multiple mechanisms in hairy cell leukemia
Nagel, S., Ehrentraut, S., Meyer, C., Kaufmann, M., Drexler, H. G., & MacLeod, R. A. F. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22253 · Cited by 17 · see citing works
Li, J., & Kalev‐Zylinska, M. L. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1170622 · Cited by 16 · see citing works
Buetti‐Dinh, A., & Friedman, R. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2145-y · Cited by 16 · see citing works
Palbociclib—The First of a New Class of Cell Cycle Inhibitors
Schmidt, M., & Sebastian, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_11 · Cited by 16 · see citing works
Learning from mouse models of MLL fusion gene-driven acute leukemia.
Schwaller, J. (2020) · Biochimica et Biophysica Acta. Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194550 · Cited by 16 · see citing works
Reikvam, H., Hauge, M., Brenner, A. K., Hatfield, K. J., & Bruserud, Ø. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1032935 · Cited by 16 · see citing works
- Authors
- Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., Armstrong, S. A., Hahn, W. C., Huntly, B. J., Sykes, S. M., Milsom, M. D., Scholl, C., & Fröhling, S.
- Affiliations
- German Cancer Research Center (DE)
- Universität Ulm (DE)
- Dana-Farber Cancer Institute (US)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Otto-von-Guericke-Universität Magdeburg (DE)
- Broad Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-07-03
- Volume
- 124
- Issue
- 1
- Pages
- 13-23
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4190617
- OpenAlex
- W1990966504
- Cited by
- 170
- References
- 60
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 6 · 2023: 11 · 2022: 16 · 2021: 19 · 2020: 24 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 17 · 2015: 23 · 2014: 6
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R00CA158461, U01CA176058, K08CA138918, P30CA008748)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- CDK6, MLL rearrangement, acute myeloid leukemia, MLL-AF9, CDK4, cell cycle regulators, myeloid differentiation, leukemogenesis, MLL fusion proteins, CDK6 inhibitors, leukemia mouse model
- MeSH terms
- Animals, Flow Cytometry, Humans, Mice, Inbred C57BL, Transduction, Genetic, Immunoblotting, Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, RNA, Small Interfering, Cell Line, Tumor, Cyclin-Dependent Kinase 6, Mice, Myeloid-Lymphoid Leukemia Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
